Xiao-Zheng Zhao

Rapid Manufactured CAR-T Cells enriched for CD45RA-negative T cells Exhibit Superior Persistence Compared to Conventional CAR-T Therapy.

CD19 CAR-T has achieved high remission rates in relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). However, rapid generation with durable in vivo persistence remains a major challenge. CD45RA-negative T cells exhibit sustained antileukemic activity and preserved immune memory. Here, we developed a rapid p...